Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20183415 | 1.00 | CYP2D6 (0.42) | CYP2D6DRD4KMT2AOPRM1OPRD1 | |
| SCHEMBL20183414 | 1.00 | CYP2D6 (0.42) | CYP2D6DRD4KMT2AOPRM1OPRD1 | |
| SCHEMBL20183378 | 1.00 | CYP2D6 (0.42) | CYP2D6DRD4KMT2AOPRM1OPRD1 | |
| SCHEMBL20183375 | 1.00 | CYP2D6 (0.42) | CYP2D6DRD4KMT2AOPRM1OPRD1 | |
| SCHEMBL28219378 | 0.84 | EPHX2 (0.40) | CYP2D6DRD4KMT2A | |
| SCHEMBL28219353 | 0.84 | EPHX2 (0.40) | CYP2D6DRD4KMT2A | |
| SCHEMBL3179052 | 0.84 | EPHX2 (0.40) | CYP2D6DRD4KMT2A | |
| SCHEMBL3179042 | 0.84 | EPHX2 (0.40) | CYP2D6DRD4KMT2A | |
| SCHEMBL20183317 | 0.83 | CYP2D6 (0.47) | CYP2D6DRD4KMT2AOPRM1OPRD1 | |
| SCHEMBL20183314 | 0.83 | CYP2D6 (0.47) | CYP2D6DRD4KMT2AOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | YANG JI CHEMICAL CO., LTD. (KR) | 2019-09-10 | — | — | US | disclosed |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | YANG JI CHEMICAL CO., LTD. (KR) | 2018-08-23 | — | — | US | disclosed |
| EP-3327021-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | Yangji Chemical Co., Ltd. (KR) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | JAK1, JAK2, JAK3 | CYP2D6 1311/4885DRD4 4869/4885KMT2A 1054/4885 |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | JAK1, JAK2, JAK3 | CYP2D6 1607/4885DRD4 4819/4885KMT2A 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.